U

nder various circumstances, the Food and Drug Administration may require a drug maker to run a post-marketing study, but a large percentage of these studies are still pending, according to the latest agency analysis.

As of the end of fiscal year 2016, 86 percent of required studies were still pending, which meant they were not yet under way. An average of 261 post-marketing requirements were made each year since fiscal year 2010, and most that were established several years ago were since fulfilled or released. Of the required studies pending as of September 30, 2016, 83 percent were created within the past three years, according to the FDA analysis.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.

X